| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 06/13/2002 | WO2002046189A2 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | WO2002046188A2 Amido ether substituted imidazoquinolines |
| 06/13/2002 | WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 06/13/2002 | WO2002046183A2 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 06/13/2002 | WO2002046182A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | WO2002046171A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046170A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046148A1 Substituted anthranilic acids |
| 06/13/2002 | WO2002046147A2 Perturbed membrane-binding compounds |
| 06/13/2002 | WO2002046134A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | WO2002045746A2 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
| 06/13/2002 | WO2002045739A1 Immunomodulatory constructs and their uses |
| 06/13/2002 | WO2002045737A2 Methods of treatment involving human mda-7 |
| 06/13/2002 | WO2002045735A2 Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus |
| 06/13/2002 | WO2002045718A1 Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells |
| 06/13/2002 | WO2002045716A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination |
| 06/13/2002 | WO2002045708A2 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 06/13/2002 | WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases |
| 06/13/2002 | WO2002028842A3 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist |
| 06/13/2002 | WO2002026929A3 Kini-3 motor protein and methods for its use |
| 06/13/2002 | WO2002026218A3 Fatty acid analogues for the treatment of proliferative skin disorders |
| 06/13/2002 | WO2002024224A3 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen |
| 06/13/2002 | WO2002022130A3 Means for regulating immune defences |
| 06/13/2002 | WO2002020038A3 Method for down-regulating ige |
| 06/13/2002 | WO2002020012A3 Method for treating allergies using substituted pyrazoles |
| 06/13/2002 | WO2002020011A3 A method for treating allergies using substituted pyrazoles |
| 06/13/2002 | WO2002019996A3 Prevention of acute sinusitis and sinus attack |
| 06/13/2002 | WO2002014315A3 Substituted pyrazoles |
| 06/13/2002 | WO2002012339A3 Sequences for integrin alpha-8 |
| 06/13/2002 | WO2002009746A3 Vaccines comprising outer membrane vesciles from gram negative bacteria |
| 06/13/2002 | WO2002000657A3 Condensed pyrazindione derivatives |
| 06/13/2002 | WO2002000252A3 Non-human animal models of tolerance to hepatitis c virus immunogenes |
| 06/13/2002 | WO2002000249A3 Multivalent vaccine composition |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001092294A3 Therapeutic anti-melanoma compounds |
| 06/13/2002 | WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 06/13/2002 | WO2001087981A3 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 06/13/2002 | WO2001083785A3 Regulated antigen delivery system (rads) involving bacteria |
| 06/13/2002 | WO2001078748A3 Immunomodulatory methods using carbohydrate antigens |
| 06/13/2002 | WO2001072277A3 Immunotherapeutic methods and compositions |
| 06/13/2002 | WO2001042461A3 Apoptin-associating protein |
| 06/13/2002 | WO2001010444A3 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 06/13/2002 | WO2000061736A9 Recombinant and mutant marek's disease virus |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072616 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 06/13/2002 | US20020072609 Process for preparing arylacetylaminothiazoles |
| 06/13/2002 | US20020072603 Novel IL-5 inhibiting 6-azauracil derivatives |
| 06/13/2002 | US20020072588 Recombinant antibody fragments as autoantibody antagonists |
| 06/13/2002 | US20020072529 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma |
| 06/13/2002 | US20020072528 Are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit T-helper-type 2 immune response; useful for therapy of viral and neoplastic diseases |
| 06/13/2002 | US20020072523 For therapy of inflammatory and immune diseases |
| 06/13/2002 | US20020072510 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 06/13/2002 | US20020072504 Method and reagents for genetic immunization |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020072090 Hr-1 receptor |
| 06/13/2002 | US20020071840 Method of therapeutic administration of anti-CD40L compounds |
| 06/13/2002 | US20020071839 Downmodulating the immune response to an intestinal allograft in a subject comprising administering an antibody that binds to B7-1 and an antibody that binds to B7-2. |
| 06/13/2002 | US20020071835 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 06/13/2002 | US20020071832 Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| 06/13/2002 | US20020071829 Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| 06/13/2002 | US20020071825 Methods and compositions for inducing an immune response |
| 06/13/2002 | US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer. |
| 06/13/2002 | DE10061334A1 Verwendung von aus embryonalen Stammzellen hergeleiteten Zellen zur Erhöhung der Transplantationstoleranz und zur Wiederherstellung zerstörten Gewebes Using derived from embryonic stem cells to increase transplant tolerance and restore damaged tissue |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2436916A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | CA2436870A1 Substituted anthranilic acids |
| 06/13/2002 | CA2436856A1 Immunomodulatory constructs and their uses |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436666A1 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | CA2431193A1 Sequences upstream of the carp gene, vectors containing them and uses thereof |
| 06/13/2002 | CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | CA2431166A1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | CA2430993A1 G-protein coupled receptors |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430769A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | CA2430624A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430376A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2428390A1 Enzymes |
| 06/13/2002 | CA2428208A1 Lipid-associated molecules |
| 06/13/2002 | CA2428097A1 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 06/13/2002 | CA2427820A1 Method of producing biospecific molecules by protein trans-splicing |
| 06/12/2002 | EP1213289A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 06/12/2002 | EP1212616A2 Inhibitors of binding between proteins and macromolecular ligands |
| 06/12/2002 | EP1212436A2 Protein phosphatase and kinase proteins |
| 06/12/2002 | EP1212422A2 Human ctla-4 antibodies and their uses |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212415A1 Pgrp-l polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212408A2 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |